Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05128071 · ClinicalTrials.gov registry record · Early Phase 1
PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)
A Early Phase 1 study of Methamphetamine-dependence and Postpartum Abstinence, sponsored by University of Utah.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05128071 is a Early Phase 1 study of Methamphetamine-dependence and Postpartum Abstinence that is actively recruiting participants, run by University of Utah. The registered enrollment target is 40 participants, below the 104-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05128071, a Early Phase 1 study of Methamphetamine-dependence and Postpartum Abstinence, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The PRevention Of Methamphetamine Use among Postpartum Women Trial (PROMPT) is randomized controlled trial of postpartum individuals with methamphetamine use disorder to 12 weeks of 200 mg oral micronized progesterone twice daily or placebo. The aims of this study are to assess the feasibility, safety and preliminary efficacy of micronized progesterone for the prevention of return to methamphetamine use. A secondary aim is to assess participant's salivary levels of allopregnanolone with methamphetamine cravings. This study has the potential to provide effective interventions to prevent methamphetamine use among postpartum women.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Progesterone
Study Locations (1)
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-02-04 |
| Est. Completion | 2027-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05128071
The ClinicalTrials.gov registry entry for NCT05128071 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (62% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Methamphetamine-dependence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05128071 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT05128071 about?
NCT05128071 is a clinical study titled "PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)". The PRevention Of Methamphetamine Use among Postpartum Women Trial (PROMPT) is randomized controlled trial of postpartum individuals with methamphetamine use disorder to 12 weeks of 200 mg oral micronized progesterone twice daily or placebo. The aims of this study are to assess the feasibility, safe...
What is the current status of trial NCT05128071?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2022-02-04. Estimated completion is 2027-04.
What conditions does trial NCT05128071 study?
This clinical trial studies the following conditions: Methamphetamine-dependence, Postpartum Abstinence.
What interventions are being tested in trial NCT05128071?
The interventions under investigation include: Placebo (DRUG), Progesterone (DRUG).
Who is sponsoring clinical trial NCT05128071?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05128071 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine-dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
COMPLETED · Early Phase 1
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
RECRUITING · Phase 3
-
Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives
RECRUITING · NA
-
rTMS for Craving in Methamphetamine Use Disorder
RECRUITING · NA
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.